



## COMPANY OVERVIEW

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies for the treatment of cancer. The Company's investigational technology, ImmunoPulse®, is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, OncoSec's lead program, ImmunoPulse® IL-12, demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. ImmunoPulse® IL-12 is currently in Phase II development for several indications, including metastatic melanoma and triple negative breast cancer. In addition to ImmunoPulse® IL-12, the Company is also seeking to identify and develop new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit [www.oncosec.com](http://www.oncosec.com).

## RECENT NEWS

### OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

May 8 2018, 7:30 AM EDT

### OncoSec to Present at Eighth Annual BioNJ BioPartnering Conference

May 3 2018, 8:00 AM EDT

## STOCK OVERVIEW

Symbol	ONCS	Exchange	NASDAQ
Shares OS	51,482,206	Market Cap	\$85.98M
Last Price	<b>\$1.67</b>	52-Week Range	<b>\$0.88 - \$2.95</b>
Fiscal Year End	<b>December 31</b>		

## MANAGEMENT TEAM

### Daniel J. O'Connor

Chief Executive Officer, President and Director

### Richard B. Slansky

Chief Financial Officer

### Christopher G. Twitty, Ph.D.

Chief Scientific Officer

### Sharron Gargosky, PhD

Chief Clinical and Regulatory Officer

## ONCOSEC MEDICAL INCORPORATED

5820 Nancy Ridge Drive  
San Diego, CA 92121  
US

## INVESTOR RELATIONS

T: 855-ONCOSEC (855-662-6732)  
[investors@oncosec.com](mailto:investors@oncosec.com)

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.